Novozymes
Novonesis (formerly Novozymes) is a Danish biosolutions company that produces and sells industrial enzymes, microbial solutions, and probiotics to B2B customers across bioenergy, food and beverages, household care, human health, industrial bioprocessing, and animal and plant health worldwide.
- Company typePublic
- Founded2000
- HeadquartersBagsværd, Denmark
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novozymes does
Novozymes A/S, operating as part of Novonesis Group following its 2025 merger with Chr. Hansen, is a Danish biotechnology company headquartered in Bagsværd, Denmark, that designs, produces, and sells industrial enzymes, microbial solutions, and probiotics to business customers across six end markets: bioenergy, food and beverages, household care, human health, industrial bioprocessing, and animal and plant health. Its core technology is biological — proprietary enzyme platforms (including Innova Apex and Innova Turbo introduced in July 2022), microbial strain libraries (notably the BB-12 Bifidobacterium probiotic strain, described as the world's most documented), and fermentation-based production processes. The company has applied AI-driven protein engineering to compress enzyme discovery timelines by an estimated 30–40%, and operates a global direct enterprise sales force plus the now-wholly-owned dsm-firmenich Feed Enzyme Alliance distribution footprint built over more than 25 years.
Novonesis (as the combined entity is branded) sells biological ingredients that customers embed into their own industrial processes — biofuel producers seeking yield improvements, food processors extending shelf life, detergent formulators replacing harsher chemistry, animal nutrition producers reducing antibiotic reliance, and consumer health brands commercializing probiotic supplements. The merger created the world's largest biosolutions company and is reported at a market capitalization of approximately $24.89 billion as of April 2026.
The business model is B2B ingredient supply with enterprise pricing negotiated directly with industrial customers and channel partners across North America, Europe, Asia-Pacific, Latin America, and emerging markets. Revenue mechanics are anchored in volume-based product sales rather than subscription contracts, though long qualification cycles and customer process integration create high revenue stickiness. Recent disclosed financial performance includes Q1 2026 revenue of $1.18B, 7% organic sales growth, a 37.8% adjusted EBITDA margin, and 2026 guidance of 5–7% organic growth with continued margin expansion to 37–38%.
Novozymes firmographics
Firmographics- Name
- Novozymes
- Legal name
- Novozymes A/S
- Website
- https://novozymes.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Novonesis (formerly Novozymes) is a Danish biosolutions company that produces and sells industrial enzymes, microbial solutions, and probiotics to B2B customers across bioenergy, food and beverages, household care, human health, industrial bioprocessing, and animal and plant health worldwide.
- Ownership category
- akta.pro rank
Novozymes industry classification
Industry- Product category
- Industrial Biotechnology (Biosolutions)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Novozymes is headquartered
LocationHeadquarters
- HQ city
- Bagsværd
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Novozymes business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales
Revenue model
- Enzyme and Biosolutions Product Sales: Novonesis generates revenue primarily through the sale of industrial enzymes, microbial solutions, and biosolutions across multiple end markets including bioenergy, food & beverages, household care, human health, industrial bioprocessing, and animal & plant health. Revenue is driven by diverse sales across multiple industries and regions.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Novozymes product offering
Product offeringCore offering
Novonesis (formerly Novozymes A/S) develops, manufactures, and sells industrial enzymes, microbial solutions, and probiotics (biosolutions) for bioenergy, food & beverages, household care, human health, industrial bioprocessing, and animal & plant health applications. The company sells directly to industrial customers and through strategic channel partnerships, offering proprietary platforms such as Innova Apex, Innova Turbo, and the BB-12 probiotic strain.
Product overview
Novonesis (formerly Novozymes A/S, now part of Novonesis Group following its merger with Chr. Hansen) operates as a biosolutions company offering a unified portfolio of enzymes, microorganisms, and probiotics across six industry verticals: Bioenergy (including Biodiesel, Biogas, Biomass, Carbon capture, Ethanol, and Renewable diesel), Food & Beverages (with enzyme solutions for baking and sensory applications), Household Care (laundry and cleaning enzymes), Human Health (probiotics and postbiotics including the BB-12 strain), Industrial Bioprocessing, and Animal & Plant (feed enzymes, probiotics, and prebiotics for aquaculture and livestock). The company delivers biological solutions that transform industries from agriculture to bioenergy, helping customers produce more from less while reducing environmental impact.
Differentiator
Problem solved
Functional benefit
Brands
- Innova Apex: Enzyme platform introduced July 2022
- Innova Turbo
- BB-12
Products and services
- Bioenergy Biosolutions
Quantifiable outcome
- 7% organic sales growth in Q1 2026
- +4 more outcomes
Companies that use Novozymes
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles6 records
Novozymes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Novozymes partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- UndoAgeminorNovozymes signed a Memorandum of Understanding with UndoAge to co-develop probiotics and postbiotics for the Chinese consumer health market. This partnership leverages Novozymes' microbial expertise to enter the emerging Chinese consumer health market with innovative probiotic and postbiotic products.
- dsm-firmenichcoreNovozymes and dsm-firmenich have worked together for over 25 years on innovating and distributing enzymes for animals as the Feed Enzyme Alliance. Novonesis has now acquired dsm-firmenich's share of the Feed Enzyme Alliance, bringing sales and distribution activities under the same roof as research and innovation. This enables the company to unlock more of the hidden potential of enzymes, microbes, and probiotics for animals, producers, and the entire value chain.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Novozymes competitors and assessment
Company assessmentEmerging players
- Codexis: Specialist protein engineering company using AI-driven directed evolution to design novel enzymes for pharmaceuticals and industrial biotech. Competes at the technology layer and is a potential disruptor in high-value enzyme niches.
Broad incumbents
- Kerry Group: Taste and nutrition company serving food and beverage customers with enzymes, cultures, and functional ingredients. Overlaps with Novonesis's food & beverage segment and competes for the same CPG customer wallets.
- BASF: Diversified chemical giant with an enzymes and biosolutions portfolio serving food, feed, and industrial customers. Competes with Novonesis as part of a much broader chemistry offering rather than a focused biosolutions strategy.
Direct peers
- AB Enzymes (Associated British Foods): Specialist industrial enzyme manufacturer serving baking, beverage, and animal feed markets. Direct competitor to Novonesis's enzyme portfolio, particularly in food processing and grain processing enzymes.
- Amano Enzyme: Japanese enzyme manufacturer producing industrial, food, and diagnostic enzymes. Direct competitor in food and beverage enzymes with strong presence in Asia-Pacific, complementing Novonesis's regional footprint.
- Lesaffre: Global yeast and fermentation products company with growing presence in probiotics and bioactives. Comparable fermentation expertise and overlap in baking, food, and human/animal nutrition probiotics.
- International Flavors & Fragrants (IFF): IFF merged with DuPont's Nutrition & Biosciences division, creating the largest direct competitor to Novonesis in enzymes, cultures, and food/feed biosolutions. Highly comparable across industrial enzymes, probiotics, and food ingredients.
- Lallemand: Private Canadian yeast, bacteria, and probiotic producer serving baking, animal nutrition, and human health. Direct competitor in microbial solutions and probiotics with comparable go-to-market in food and animal health.
- dsm-firmenich: Global nutrition, health, and biosciences company with overlapping capabilities in animal nutrition enzymes, vitamins, and flavors. Former Feed Enzyme Alliance partner of Novozymes; competes in human and animal nutrition.
Others
- Chr. Hansen (now part of Novonesis): Historical direct peer in probiotics and microbial solutions; now merged into Novonesis. Pre-merger it was a comparable biosolutions platform and remains a useful benchmark for understanding Novonesis's combined product mix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Novozymes social profiles
Digital presenceNovozymes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novozymes leadership team
Management profileNumber of profiles
Profiles9 records
Novozymes subsidiaries and ownership
Company hierarchySubsidiaries1 record
Novozymes funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novozymes M&A and investment
M&A and investmentM&A16 records
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novozymes
What does Novozymes do?
Novonesis (formerly Novozymes A/S) develops, manufactures, and sells industrial enzymes, microbial solutions, and probiotics (biosolutions) for bioenergy, food & beverages, household care, human health, industrial bioprocessing, and animal & plant health applications. The company sells directly to industrial customers and through strategic channel partnerships, offering proprietary platforms such as Innova Apex, Innova Turbo, and the BB-12 probiotic strain.
Is Novozymes a public or private company?
Novozymes is a public company. It is classified as public and is currently operating.
When was Novozymes founded?
Novozymes was founded in 2000. It employs 5,001 to 10,000 people.
Where is Novozymes based?
Novozymes is headquartered in Bagsværd, Denmark, in the Europe region.
How does Novozymes make money?
One revenue line is on record: enzyme and Biosolutions Product Sales.
Who are Novozymes's main competitors?
Codexis is listed as an emerging player. Broad incumbents are Kerry Group and BASF. Direct peers are AB Enzymes (Associated British Foods), Amano Enzyme, Lesaffre, International Flavors & Fragrants (IFF), Lallemand and dsm-firmenich. Chr. Hansen (now part of Novonesis) is listed as an others.
Does Novozymes have an API?
No public API is recorded for Novozymes.
What industry is Novozymes in?
Novozymes's product category is Industrial Biotechnology (Biosolutions). Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325414 and its SIC code is 2836.